Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Average Recommendation of “Buy” from Analysts

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has earned an average rating of “Buy” from the eighteen analysts that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $285.4444.

JAZZ has been the topic of several research analyst reports. Weiss Ratings raised Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. TD Cowen increased their price target on shares of Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Morgan Stanley raised their price objective on shares of Jazz Pharmaceuticals from $283.00 to $322.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 26th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. Finally, UBS Group reiterated a “buy” rating and set a $315.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 4th.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, Director Mark Douglas Smith sold 1,157 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $230.55, for a total value of $266,746.35. Following the transaction, the director directly owned 9,680 shares in the company, valued at approximately $2,231,724. This trade represents a 10.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the transaction, the executive vice president directly owned 51,549 shares in the company, valued at approximately $11,950,604.67. The trade was a 2.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 91,278 shares of company stock valued at $22,712,816 in the last quarter. 4.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Triumph Capital Management lifted its stake in shares of Jazz Pharmaceuticals by 2.0% in the 2nd quarter. Triumph Capital Management now owns 2,597 shares of the specialty pharmaceutical company’s stock worth $626,000 after acquiring an additional 52 shares during the period. Cardinal Capital Management increased its stake in shares of Jazz Pharmaceuticals by 0.5% during the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock worth $2,471,000 after acquiring an additional 66 shares during the period. Bessemer Group Inc. increased its stake in shares of Jazz Pharmaceuticals by 0.3% during the first quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock worth $4,228,000 after acquiring an additional 73 shares during the period. UMB Bank n.a. raised its holdings in Jazz Pharmaceuticals by 12.6% during the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 81 shares in the last quarter. Finally, Pinnacle Associates Ltd. raised its holdings in Jazz Pharmaceuticals by 0.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after purchasing an additional 83 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $243.71 on Wednesday. The stock’s 50-day moving average is $248.07 and its two-hundred day moving average is $219.83. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58. Jazz Pharmaceuticals has a 1-year low of $123.88 and a 1-year high of $266.38. The company has a market cap of $15.82 billion, a price-to-earnings ratio of 16.81, a price-to-earnings-growth ratio of 0.23 and a beta of 0.36.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. During the same period last year, the business earned ($8.25) EPS. The firm’s revenue was up 15.5% compared to the same quarter last year. Analysts forecast that Jazz Pharmaceuticals will post 21.5 EPS for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.